Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis
Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis have?
Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis has 65 citations in the OpenAlex counts ScholarIQ stores.
When was Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis published?
Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis has 2015 year in the ScholarIQ index.
What is the open-access status of Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis?
Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis has closed oa status in the ScholarIQ index.
What is the DOI of Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis?
The DOI for Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis is on the source record.
What is the PMID of Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis?
The PMID for Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis is on the source record.
What is the OpenAlex record for Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis?
The OpenAlex for Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis is on the source record.